According to the trading public information released by the Shanghai and Shenzhen Stock Exchanges on January 20, 2022, Yabao Pharmaceutical (600351) has been listed on the Dragon and Tiger List due to the cumulative deviation of the closing price decline of non-ST, *ST and S securities in three consecutive trading days. This is the second time in the last 5 trading days to make the list.
As of the close, Yabao Pharmaceutical closed at 8.05 yuan, down -3.71%, with a trading volume of 709,200 lots.
Yabao Pharmaceutical (600351) focuses on:
1. Aggretin hydrochloride and SY-008, a new oral drug for the treatment of type II diabetes mellitus, have entered the clinical phase I; at present, the clinical approval for acute stroke and type II diabetes in the new drug project under research has been obtained
2. One of the main products is to reduce swelling and relieve pain, and the main therapeutic function of the patch is to clear heat and reduce swelling, relieve pain, and can play a role in quick-acting pain relief and high efficiency anti-inflammatory, which is a special topical patch of traditional Chinese medicine; in terms of innovative drugs, there are two new types of new oral diabetes drugs that have obtained clinical approvals and entered the phase I clinical stage; they have been treated as new injection drugs for stroke and new oral drugs for the treatment of diabetes
3, plaster faucet, patented product Ding Gui'er umbilical patch is the first brand of domestic children's external medicine, can play a role in quick-acting pain relief and diarrhea; core products include Ding Gui'er umbilical patch, swelling and pain relief patch, lipoic acid injection, safflower injection, mosalpride citrate tablets, nifedipine sustained release tablets, etc., covering children's drugs and cardiovascular and other fields; 20 years of pharmaceutical production revenue of 2.126 billion yuan, revenue accounted for 81.70%
The unit has not had an institutional rating in the last 90 days. In the past three months, the net inflow of financing was 237 million, and the balance of financing increased; the net inflow of margin was 636,700, and the balance of margin increased. The Valuation Analysis Tool of Securities Star shows that Yabao Pharmaceutical (600351) has a good company rating of 2.5 stars, a good price rating of 2 stars, and a comprehensive valuation rating of 2.5 stars. (Rating Range: 1 ~ 5 stars, maximum 5 stars)
This article is compiled by the Securities Star Data Center based on publicly available data and does not constitute investment opinions or suggestions, if you have any questions, please contact us.